Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Med Chem ; 44(11): 1675-89, 2001 May 24.
Article in English | MEDLINE | ID: mdl-11356103

ABSTRACT

A stepwise chemical modification from human neurokinin-3 receptor (hNK-3R)-selective antagonists to potent and combined hNK-3R and hNK-2R antagonists using the same 2-phenylquinoline template is described. Docking studies with 3-D models of the hNK-3 and hNK-2 receptors were used to drive the chemical design and speed up the identification of potent and combined antagonsits at both receptors. (S)-(+)-N-(1-Cyclohexylethyl)-3-[(4-morpholin-4-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 25, SB-400238: hNK-3R binding affinity, K(i) = 0.8 nM; hNK-2R binding affinity, K(i) = 0.8 nM) emerged as the best example in this approach. Further studies led to the identification of (S)-(+)-N-(1,2,2-trimethylpropyl)-3-[(4-piperidin-1-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 28, SB-414240: hNK-3R binding affinity, K(i) = 193 nM; hNK-2R binding affinity, K(i) = 1.0 nM) as the first hNK-2R-selective antagonist belonging to the 2-phenylquinoline chemical class. Since some members of this chemical series showed a significant binding affinity for the human mu-opioid receptor (hMOR), docking studies were also conducted on a 3-D model of the hMOR, resulting in the identification of a viable chemical strategy to avoid any significant micro-opioid component. Compounds 25 and 28 are therefore suitable pharmacological tools in the tachykinin area to elucidate further the pathophysiological role of NK-3 and NK-2 receptors and the therapeutic potential of selective NK-2 (28) or combined NK-3 and NK-2 (25) receptor antagonists.


Subject(s)
Morpholines/chemical synthesis , Piperidines/chemical synthesis , Quinolines/chemical synthesis , Receptors, Neurokinin-2/antagonists & inhibitors , Receptors, Neurokinin-3/antagonists & inhibitors , Amino Acid Sequence , Animals , CHO Cells , Cloning, Molecular , Cricetinae , Humans , Models, Molecular , Molecular Sequence Data , Morpholines/chemistry , Morpholines/metabolism , Piperidines/chemistry , Piperidines/metabolism , Quinolines/chemistry , Quinolines/metabolism , Radioligand Assay , Receptors, Neurokinin-2/chemistry , Receptors, Neurokinin-2/metabolism , Receptors, Neurokinin-3/chemistry , Receptors, Neurokinin-3/metabolism , Receptors, Opioid, mu/chemistry , Receptors, Opioid, mu/metabolism , Structure-Activity Relationship
2.
Pharmacology ; 62(2): 113-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11174082

ABSTRACT

A series of phenylethanolamines bearing a 2-[1-phenylpropyl] substituent on the nitrogen atom was evaluated in vitro for activity at beta(1)- and beta(2)-adrenoceptors. As previously observed, the presence of 3,4-dihydroxy substitution on phenylethanolamine is required for potent activation of both subtypes, whereas the 3,5-dihydroxy analog showed selectivity for the beta(2)-subtype. Replacement by a carboxyl group of the 4-hydroxyl group on the aralkyl nitrogen substituent produced only a small reduction in beta(1) potency (5-fold), whereas beta(2) potency was reduced by more than 100-fold. Hence this structural class includes agonists having either a beta(1), nonselective beta(1)/beta(2) or beta(2) selectivity profile.


Subject(s)
Adrenergic beta-Agonists/pharmacology , Isoproterenol/pharmacology , Muscle Relaxation/drug effects , Myocardial Contraction/drug effects , Receptors, Adrenergic, beta-1/drug effects , Receptors, Adrenergic, beta-2/drug effects , Adrenergic beta-Agonists/chemistry , Animals , Atrial Function, Right/drug effects , Atrial Function, Right/physiology , Ethanolamines/chemistry , Ethanolamines/pharmacology , Guinea Pigs , Isoproterenol/chemistry , Male , Muscle Relaxation/physiology , Myocardial Contraction/physiology , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, beta-1/physiology , Receptors, Adrenergic, beta-2/physiology , Structure-Activity Relationship , Trachea/drug effects , Trachea/physiology
3.
Farmaco ; 54(6): 364-74, 1999 Jun 30.
Article in English | MEDLINE | ID: mdl-10443017

ABSTRACT

Results from a medicinal chemistry approach aimed at replacing the quinoline ring system in the potent and selective human neurokinin-3 (hNK-3) receptor antagonists 1-4 of general formula I are discussed. The data give further insight upon the potential NK-3 pharmacophore. In particular, it is highlighted that both the benzene-condensed ring and the quinoline nitrogen are crucial determinants for optimal binding affinity to the hNK-3 receptor. Some novel compounds maintained part of the binding affinity to the receptor (5, 6, 10 and 13) and compound 5, featuring the naphthalene ring system, appears to be suitable for further modifications; it offers the option to introduce electron-withdrawing groups at position 2 and 4, conferring on the ring an overall electron-deficiency similar to that of the quinoline.


Subject(s)
Quinolines/chemical synthesis , Quinolines/pharmacology , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Binding, Competitive/drug effects , CHO Cells , Cloning, Molecular , Cricetinae , Humans , Radioligand Assay , Structure-Activity Relationship
4.
J Med Chem ; 42(6): 1053-65, 1999 Mar 25.
Article in English | MEDLINE | ID: mdl-10090788

ABSTRACT

Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SB 223412, hNK-3-CHO binding Ki = 1.4 nM) and 55 (3-NH2, hNK-3-CHO binding Ki = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 microM. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SB 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.


Subject(s)
Quinolines/chemical synthesis , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , CHO Cells , Calcium/metabolism , Cell Line , Cloning, Molecular , Cricetinae , Humans , In Vitro Techniques , Iris/drug effects , Iris/physiology , Mice , Miosis/physiopathology , Motor Activity/drug effects , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Peptide Fragments/pharmacology , Quinolines/chemistry , Quinolines/metabolism , Rabbits , Radioligand Assay , Receptors, Neurokinin-3/biosynthesis , Structure-Activity Relationship , Substance P/analogs & derivatives , Substance P/pharmacology
5.
J Med Chem ; 40(12): 1794-807, 1997 Jun 06.
Article in English | MEDLINE | ID: mdl-9191956

ABSTRACT

A novel class of potent and selective non-peptide neurokinin-3 (NK-3) receptor antagonists, featuring the 4-quinolinecarboxamide framework, has been designed based upon chemically diverse NK-1 receptor antagonists. The novel compounds 33-76, prompted by chemical modifications of the prototype 4, have been characterized by binding analysis using a membrane preparation of chinese hamster ovary (CHO) cells expressing the human neurokinin-3 receptors (hNK-3-CHO), and clear structure-activity relationships (SARs) have been established. From SARs, (R)-N-[alpha-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide (65, SB 218795, hNK-3-CHO binding Ki = 13 nM) emerged as one of the most potent compounds of this novel class. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 65 is about 90-fold selective for hNK-3 versus hNK-2 receptors (hNK-2-CHO binding Ki = 1221 nM) and over 7000-fold selective versus hNK-1 receptors (hNK-1-CHO binding Ki = > 100 microM). In vitro functional studies in rabbit isolated iris sphincter muscle preparation demonstrated that 65 is a competitive antagonist of the contractile response induced by the potent and selective NK-3 receptor agonist senktide with a Kb = 43 nM. Overall, the data indicate that 65 is a potent and selective hNK-3 receptor antagonist and a useful lead for further chemical optimization.


Subject(s)
Quinolines/chemical synthesis , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Binding, Competitive , CHO Cells , Chemical Phenomena , Chemistry, Physical , Cricetinae , Humans , Hydrogen Bonding , Molecular Structure , Muscle Contraction/drug effects , Peptide Fragments/pharmacology , Quinolines/metabolism , Rabbits , Receptors, Neurokinin-3/genetics , Receptors, Neurokinin-3/metabolism , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship , Substance P/analogs & derivatives , Substance P/pharmacology
6.
Int J Clin Lab Res ; 27(2): 123-8, 1997.
Article in English | MEDLINE | ID: mdl-9266283

ABSTRACT

To investigate whether early postoperative changes in blood lactate concentration indicate the functional recovery of the newly grafted liver, changes in oxygen supply, oxygen consumption, acid-base equilibrium, and blood lactate concentrations were prospectively studied in a group of 53 postnecrotic cirrhotic patients during the various phases of orthotopic liver transplantation (preanhepatic, anhepatic, neohepatic) and for the first 48 h following reperfusion. The patients were divided into two groups according to the quality of the early graft function, as indicated by alanine aminotransferase, bile flow, and prothrombin activity: group A (49 patients), good immediate graft function and group B (4 patients), immediate graft non-function. Lactate levels rose in the same manner during the preanhepatic and anhepatic stages and peaked after revascularization of the graft. Following reperfusion, however, distinctly different blood lactate profiles were recorded in the two groups of patients. A fall in lactate concentration was recorded in group A patients, whereas a continuous rise occurred in group B patients: the difference becoming significant by the end of surgery (P < or = 0.05). During the first 48 h following revascularization of the graft, opposite trends in lactate concentration, bile flow, alanine aminotransferase, and prothrombin activity were evident in the two groups of patients: 24 h after reperfusion, lactate levels were below 2 mmol/l in 47 of 49 patients from group A, while they plateaued above 4 mmol/l in all patients from group B. Group A patients had lower alanine aminotransferase levels (P < or = 0.001), higher prothrombin activity, (P < or = 0.01), and greater bile flow (P < or = 0.02). If validated in larger series, the blood lactate profile, probably more than the absolute level, appears to be a useful indicator of the early recovery of liver metabolic capacities in the immediate postoperative period of orthotopic liver transplantation.


Subject(s)
Lactates/blood , Liver Cirrhosis/blood , Liver Cirrhosis/surgery , Liver Transplantation , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Bile/metabolism , Graft Survival/physiology , Humans , Intraoperative Period , Liver Cirrhosis/pathology , Necrosis , Postoperative Period , Prothrombin Time
8.
Farmaco ; 50(6): 405-18, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7669179

ABSTRACT

Over the past decade there has been great interest by the pharmaceutical industry in the development of novel analgesics which act by activation of central kappa-opioid receptors. However, in view of the spectrum of unwanted CNS effects associated with such agents, recent efforts have been focused on peripherally-selective compounds with limited ability to cross the blood-brain barrier (BBB). In this review, the authors consider the chemical strategies and associated synthetic procedures employed by various research groups to produce hydrophilic compounds with retained kappa-opioid agonist activity. Physico-chemical (clogP, delta logP) and biological methods (antinociception following administration by peripheral and central routes; ex-vivo binding to detect plasma and brain levels of the drugs) utilized to assess brain penetration are described and compared. Overall, in-vivo ratios correlate better with delta logP values than with clogP.


Subject(s)
Analgesics/chemical synthesis , Blood-Brain Barrier/drug effects , Central Nervous System/drug effects , Peripheral Nervous System/drug effects , Receptors, Opioid, kappa/agonists , Analgesics/pharmacokinetics , Analgesics/pharmacology , Animals , Humans , Lethal Dose 50
9.
Recenti Prog Med ; 81(11): 705-9, 1990 Nov.
Article in Italian | MEDLINE | ID: mdl-1962892

ABSTRACT

This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levo-rotatory betablocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized: 10 received 40 mg/day of penbutolol orally and the others a placebo. Angioscintigraphy was performed before and after an 8-day treatment period. Three cases in the penbutolol group were lost due to software damage, hence the data of 17 patients were analyzed. The two groups were similar for age, sex, etiology of cirrhosis and hepatic function. The index of portal perfusion decreased significantly (-29%; p = 0.018), and the hepatic artery index increased significantly (+23%; p = 0.018), whereas no changes were observed after placebo. The heart rate decreased significantly after penbutolol (-9%; p = 0.021); while neither penbutolol nor placebo modified the ejection fraction. In conclusion, penbutolol decreased portal perfusion index (the compensatory increase of hepatic artery index confirmed this change) without significant modification of total hepatic blood flow and systemic hemodynamics. Angioscintigraphy is reasonably accurate, reproducible, safe and can be considered suitable for routine use in the assessment of liver hemodynamics.


Subject(s)
Liver Cirrhosis/drug therapy , Liver/drug effects , Penbutolol/therapeutic use , Administration, Oral , Double-Blind Method , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Hypertension, Portal/diagnostic imaging , Hypertension, Portal/drug therapy , Hypertension, Portal/physiopathology , Liver/diagnostic imaging , Liver/physiopathology , Liver Circulation/drug effects , Liver Circulation/physiology , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/physiopathology , Radionuclide Angiography , Sodium Pertechnetate Tc 99m
10.
Hepatogastroenterology ; 37(4): 398-402, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2210607

ABSTRACT

This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levorotatory beta-blocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized to two groups: 10 received 40 mg/day of penbutolol orally and the others placebo. Angioscintigraphy was performed before and after an 8-day treatment period. Three cases in the penbutolol group were lost due to software damage, hence the data of 17 patients were analyzed. The two groups were matched for age, sex, etiology of cirrhosis and hepatic function. The index of portal perfusion decreased significantly (-29%; p = 0.018) and the hepatic artery index increased significantly (+23%; p = 0.018), while no changes were observed after placebo. The heart rate decreased significantly after penbutolol (-9%; p = 0.028), while neither penbutolol nor placebo modified the ejection fraction. In conclusion, penbutolol decreased portal perfusion index (the compensatory increase in the hepatic artery index confirmed this change) without major modification of total hepatic blood flow or systemic hemodynamics. Angioscintigraphy is reasonably accurate, reproducible, safe and can be considered suitable for routine use in the assessment of liver hemodynamics.


Subject(s)
Hypertension, Portal/drug therapy , Liver Circulation/drug effects , Liver Cirrhosis/complications , Penbutolol/therapeutic use , Portal System/drug effects , Double-Blind Method , Female , Humans , Hypertension, Portal/diagnostic imaging , Hypertension, Portal/etiology , Male , Middle Aged , Portal System/diagnostic imaging , Radionuclide Angiography
SELECTION OF CITATIONS
SEARCH DETAIL
...